参考文献/References:
[1] Farina GS,Kalil C,Gutiérrez JP,et al. Arterial stiffness:a possible predictor of atrial fibrillation[J]. Rev Cardiovasc Med,2022,23(1):32.
[2] Aune D,Mahamat-Saleh Y,Kobeissi E,et al. Blood pressure,hypertension and the risk of atrial fibrillation:a systematic review and meta-analysis of cohort studies[J]. Eur J Epidemiol,2023,38(2):145-178.
[3] 金晖,杨东辉. 中外心房颤动流行病学特点比较[J]. 心血管病学进展,2024,45(07):622-626.
[4] Chao H,He Y,Wang Q,et al. Comparison of influence of blood pressure and carotid-femoral pulse wave velocity on target organ damage in hypertension[J]. Front Cardiovasc Med,2022,9:934747.
[5] Pilz N,Heinz V,Ax T,et al. Pulse wave velocity:methodology,clinical applications,and interplay with heart rate variability[J]. Rev Cardiovasc Med,2024,25(7):266.
[6] Almuwaqqat Z,Claxton J’S,Norby FL,et al. Association of arterial stiffness with incident atrial fibrillation:a cohort study[J]. BMC Cardiovasc Disord,2021,21(1):247.
[7] Cui X,Hu Y,Li D,et al. Association between estimated pulse wave velocity and in-hospital mortality of patients with acute kidney injury:a retrospective cohort analysis of the MIMIC-IV database[J]. Ren Fail,2024,46(1):2313172.
[8] Michaud GF,Stevenson WG. Atrial fibrillation[J]. N Engl J Med,2021,384(4):353-361.
[9] Cheng S,He J,Han Y,et al. Global burden of atrial fibrillation/atrial flutter and its attributable risk factors from 1990 to 2021[J]. Europace,2024,26(7):euae195.
[10] Fu W,Li R. Diagnostic performance of a wearing dynamic ECG recorder for atrial fibrillation screening:the HUAMI heart study[J]. BMC Cardiovasc Disord,2021,21(1):558.
[11] Prelevi? V,Blagus L,Bo?njak V,et al. Estimated pulse wave velocity and all-cause and cardiovascular mortality in the general population[J]. J Clin Med,2024,13(12):3377.
[12] Bialonczyk U,Pstras L,Debowska M,et al. Leveraging pulse wave signal properties for coronary artery calcification screening in CKD patients[J]. Comput Biol Med,2025,194:110519.
[13] Sang DS,Zhang Q,Song D,et al. Association between brachial-ankle pulse wave velocity and cardiovascular and cerebrovascular disease in different age groups[J]. Clin Cardiol,2022,45(3):315-323.
[14] Ou W,Liu P,Zhao N,et al. Association between cumulative body mass index exposure and the risk of incident cardiac conduction block[J]. J Am Heart Assoc,2025,14(8):e039522.
[15] Zhang R,Cui C,Wang S,et al. Interaction effect of hypertension and obesity on left atrial phasic function:a three-dimensional echocardiography study[J]. Quant Imaging Med Surg,2023,13(7):4463-4474.
[16] Gui Z,Chen X,Wang D,et al. Inflammatory and metabolic markers mediate the association of hepatic steatosis and fibrosis with 10-year ASCVD risk[J]. Ann Med,2025,57(1):2486594.
[17] Choi JS,Oh SJ,Oh S. Combined impact of elevated arterial stiffness and left ventricular filling pressure on outcomes after off-pump coronary artery bypass grafting[J]. J Cardiothorac Surg,2022,17(1):248.
[18] Chen H,Chen G,Zhang L,et al. Estimated pulse wave velocity can predict the incidence of new-onset atrial fibrillation:a 11-year prospective study in a Chinese population[J]. Front Cardiovasc Med ,2022,9:912573.
[19] Esmaeili Z,Bahiraie P,Vaziri Z,et al. The association between pulse wave velocity and heart failure:a systematic review and meta-analysis[J]. Front Cardiovasc Med,2024,11:1435677.
[20] Adamopoulos D,Rovas G,Johner N,et al. Left atrial wall shear stress correlates with fibrosis in patients with atrial fibrillation[J]. Nat Cardiovasc Res,2025,4(6):677-688.
[21] Pauklin P,Eha J,Tootsi K,et al. Atrial fibrillation is associated with increased central blood pressure and arterial stiffness[J]. J Clin Hypertens (Greenwich),2021,23(8):1581-1587.
[22] Lominadze Z,Chelidze K,Chelidze L,et al. COMPARISON OF THE OSCILLOMETRICALLY MEASURED AORTIC PULSE WAVE VELOCITY,AUGMENTATION INDEX AND CENTRAL SYSTOLIC BLOOD PRESSURE BETWEEN PATIENTS WITH ACUTE CORONARY SYNDROME AND CHRONIC CORONARY SYNDROME[J]. Georgian Med News,2021,(319):58-64.
[23] Sugawara J,Tanaka H,Yamashina A,et al. Cross-sectional and longitudinal evaluation of heart-to-brachium pulse wave velocity for cardiovascular disease risk[J]. Hypertens Res,2024,47(11):3010-3024.
[24] Naser JA,Michelena HI,Lin G,et al. Incidence,risk factors,and outcomes of atrial functional mitral regurgitation in patients with atrial fibrillation or sinus rhythm[J]. Eur Heart J Cardiovasc Imaging,2023,24(11):1450-1457.
[25] Delgado V,Ajmone Marsan N,Bonow RO,et al. Degenerative mitral regurgitation[J]. Nat Rev Dis Primers,2023,9(1):70.
[26] 马振岩,阿鑫,赵蕾,等. 急性ST段抬高型心肌梗死经皮冠状动脉介入术后左心室不良重构的新型风险预测模型：基于心脏磁共振的多中心前瞻性研究[J]. 南方医科大学学报,2025,45(4):669-683.
[27] Jiang XX,Zhang R,Wang HS. Neferine mitigates angiotensin II-induced atrial fibrillation and fibrosis via upregulation of Nrf2/HO-1 and inhibition of TGF-β/p-Smad2/3 pathways[J]. Aging (Albany NY),2024,16(10):8630-8644.
[28] Kasa G,Teis A,Juncà G,et al. Clinical and prognostic implications of left ventricular dilatation in heart failure[J]. Eur Heart J Cardiovasc Imaging,2024,25(6):849-856.
[29] Portolan L,Scarsini R,Gallinoro E,et al. Resting coronary flow and long-term clinical outcomes in dilated cardiomyopathy[J]. Int J Cardiovasc Imaging,2025,41(7):1423-1435.
[30] Invers-Rubio E,Hernández-Romero I,Reventos-Presmanes J,et al. Regional conduction velocities determined by noninvasive mapping are associated with arrhythmia-free survival after atrial fibrillation ablation[J]. Heart Rhythm,2024,21(9):1570-1580.
[31] Li X,Wu X,Chen X,et al. Selective blockade of interleukin 6 trans-signaling depresses atrial fibrillation[J]. Heart Rhythm,2023,20(12):1759-1770.
[32] Bosanac J,Straus L,Novakovi? M,et al. HFpEF and atrial fibrillation:the enigmatic interplay of dysmetabolism,biomarkers,and vascular endothelial dysfunction[J]. Dis Markers,2022,2022:9539676.
[33] Neubauer K,Zieger B. Endothelial cells and coagulation[J]. Cell Tissue Res,2022,387(3):391-398.
[34] Yang HH,Chen YC,Ho CC,et al. Serum phenylacetylglutamine among potential risk factors for arterial stiffness measuring by carotid-femoral pulse wave velocity in patients with kidney transplantation[J]. Toxins (Basel),2024,16(2):111.
[35] He L,Liu R,Yue H,et al. Interaction between neutrophil extracellular traps and cardiomyocytes contributes to atrial fibrillation progression[J]. Signal Transduct Target Ther,2023,8(1):279.
[36] Rossman MJ,Santos-Parker JR,Steward C,et al. Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults[J]. Hypertension,2018,71(6):1056-1063.
[37] Wang H,Martinez Yus M,Brady T,et al. Sex differences and role of lysyl oxidase-like 2 in angiotensin II-induced hypertension in mice[J]. Am J Physiol Heart Circ Physiol,2024,327(3):H642-H659.
[38] Yuan W,Zhang X,Fan X. The role of the Piezo1 mechanosensitive channel in heart failure[J]. Curr Issues Mol Biol,2023,45(7):5830-5848.
[39] Krittayaphong R,Kaolawanich Y,Phrommintikul A,et al. The burden of atrial fibrillation and unmet needs of its management in Southeast Asia and South Asia[J]. Lancet Reg Health Southeast Asia,2025,34:100549.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(11):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(11):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(11):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(11):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(11):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(11):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(11):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(11):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(11):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(11):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]